Citadel Advisors’s Innate Pharma IPHA Stock Holding History

Citadel Advisors’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.9K	Buy	+12,441	New	+$20.6K	﹤0.01%	13375
2025 Q4	–	Sell	-20,042	Closed	-$39.1K	–	13347
2025 Q3	$39.1K	Sell	20,042 -6,575	-25%	-$13.2K	﹤0.01%	12305
2025 Q2	$46.6K	Buy	26,617 +2,350	+10%	+$4.77K	﹤0.01%	11804
2025 Q1	$43.2K	Buy	24,267 +12,414	+105%	+$24.2K	﹤0.01%	12460
2024 Q4	$21.9K	Sell	11,853 -9,414	-44%	-$17.7K	﹤0.01%	13121
2024 Q3	$48.7K	Sell	21,267 -2,260	-10%	-$4.99K	﹤0.01%	11945
2024 Q2	$45.6K	Buy	+23,527	New	+$59.1K	﹤0.01%	11867
2023 Q3	–	Sell	-13,281	Closed	-$41.7K	–	14673
2023 Q2	$41.7K	Buy	+13,281	New	+$40.8K	﹤0.01%	12025
2021 Q2	–	Sell	-25,250	Closed	-$109K	–	14025
2021 Q1	$109K	Buy	+25,250	New	+$113K	﹤0.01%	12400

Other funds holding IPHA

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Citadel Advisors's IPHA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Innate Pharma (IPHA) in Q2 2026: 12,441 shares worth $22.9K. The stake represents ﹤0.01% of the portfolio and ranks #13375 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IPHA as recently as Q3 2025.

Citadel Advisors first reported a position in IPHA in Q1 2021 and has held it in 9 quarters since. The position peaked at $109K in Q1 2021. 10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

Citadel Advisors held 12,441 shares of Innate Pharma worth $22.9K as of Q2 2026.
Innate Pharma was a new Citadel Advisors position in Q2 2026.
Innate Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13375 holding.
Citadel Advisors first reported a position in Innate Pharma in Q1 2021 and has held it in 9 quarters since.
Citadel Advisors's Innate Pharma position peaked at $109K in Q1 2021.
10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.